B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality

Blood

Volumn 125, Issue 21, 2015, Pages 3335-3346

  Veenstra, Rachelle G ^a   Flynn, Ryan ^a   Kreymborg, Katharina ^b   McDonald Hyman, Cameron ^a   Saha, Asim ^a   Taylor, Patricia A ^a   Osborn, Mark J ^a   Panoskaltsis Mortari, Angela ^a   Schmitt Graeff, Annette ^c   Lieberknecht, Elisabeth ^c   Murphy, William J ^d   Serody, Jonathan S ^e   Munn, David H ^f   Freeman, Gordon J ^g   Allison, James P ^b,h   Mak, Tak W ⁱ   Van Brink, Marcel Den ^b   Zeiser, Robert ^c   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

Absence of b7 h3 expression in allogeneic recipients or on allogeneic donor T cells leads to accelerated gvhd lethality. Increased gvhd lethality is a result of increased t cell proliferation; Colon inflammatory cytokines, and intestinal permeability

Indexed keywords

B7 H3 PROTEIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; MEMBRANE PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, MOUSE;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DONOR; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; LETHALITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TARGET ORGAN; UPREGULATION; ADVERSE EFFECTS; ALLOGRAFT; ANIMAL; BONE MARROW TRANSPLANTATION; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; POLYMERASE CHAIN REACTION;

ALLOGRAFTS; ANIMALS; B7 ANTIGENS; BONE MARROW TRANSPLANTATION; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 84979860701     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-603357     Document Type: Article

References (25)

1. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3): 269-274.
2. Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially downregulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4(9):899-906.
3. Steinberger P, Majdic O, Derdak SV, et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol. 2004;172(4): 2352-2359.
4. Saatian B, Yu XY, Lane AP, Doyle T, Casolaro V, Spannhake EW. Expression of genes for B7-H3 and other T cell ligands by nasal epithelial cells during differentiation and activation. Am J Physiol Lung Cell Mol Physiol. 2004;287(1): L217-L225.
5. Suh WK, Wang SX, Jheon AH, et al. The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization. Proc Natl Acad Sci USA. 2004;101(35):12969-12973.
6. Castriconi R, Dondero A, Augugliaro R, et al. Identification of 4Ig-B7-H3 as a neuroblastomaassociated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA. 2004;101(34):12640-12645.
7. Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H, Azuma M. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA. 2008; 105(30):10495-10500.
8. Leitner J, Klauser C, Pickl WF, et al. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 2009;39(7):1754-1764.
9. Luo L, Chapoval AI, Flies DB, et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD81 cytolytic T cells. J Immunol. 2004;173(9): 5445-5450.
10. Wang L, Fraser CC, Kikly K, et al. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol. 2005;35(2):428-438.
11. Prasad DV, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004; 173(4):2500-2506.
12. Ueno T, Yeung MY, McGrath M, et al. Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses. Eur J Immunol. 2012;42(9): 2343-2353.
13. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev. 2009; 229(1):145-151.
14. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(1)CD25(1) immune regulatory cells inhibits graft-versushost disease lethality. Blood. 2002;99(10): 3493-3499.
15. Xu J, Huang B, Xiong P, et al. Soluble mouse B7-H3 down-regulates dendritic cell stimulatory capacity to allogenic T cell proliferation and production of IL-2 and IFN-gamma. Cell Mol Immunol. 2006;3(3):235-240.
16. Nagashima O, Harada N, Usui Y, et al. B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma. J Immunol. 2008;181(6):4062-4071.
17. Petrovic A, Alpdogan O, Willis LM, et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood. 2004;103(4):1542-1547.
18. Koestner W, Hapke M, Herbst J, et al. PD-L1 blockade effectively restores strong graft-versusleukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD81 T cells. Blood. 2011;117(3):1030-1041.
19. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of CD28: B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol. 1999;162(11): 6368-6377.
20. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. JImmunol.2003;171(3): 1272-1277.
21. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2008;111(6):3257-3265.
22. Veenstra RG, Taylor PA, Zhou Q, et al. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood. 2012;120(3):682-690.
23. Saha A, Aoyama K, Taylor PA, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013;122(17):3062-3073.
24. Snider D, Liang H. Early intestinal Th1 inflammation and mucosal T cell recruitment during acute graft-versus-host reaction. J Immunol. 2001;166(10):5991-5999.
25. Kataoka Y, Iwasaki T, Kuroiwa T, et al. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology. 2001;103(3):310-318.